Condition: Myopia · Sponsor: S-Alpha Therapeutics, Inc.
The objective of this clinical trial is to collect data on the rebound effect and long-term safety of SAT-001, a Software as a Medical Device (SaMD) under development for the inhibition and treatment of myopia progression in pediatric patients.
This description comes directly from the study's public registry record.
Jihye Lee, MSc · (+82) 2-3487-3923 · sophie@salphadtx.com
Always discuss trial participation with your own doctor first.
| Kangbuk Samsung Hospital | Seoul, Choose One..., South Korea | Recruiting |
| Seoul Asan Medical Center | Seoul, Choose One..., South Korea | Not Yet Recruiting |
| Hallym University Dongtan Sacred heart Hospital | Hwaseong-si, Gyeonggi-do, South Korea | Recruiting |
| Chung-Ang University Gwang Myeong Hospital | Gwangmyeong, South Korea | Not Yet Recruiting |
| Gachon University Gil Medical Center | Incheon, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06742268